key: cord-0292882-mjahzh5l
authors: Duerr, R.; Dimartino, D.; Marier, C.; Zappile, P.; Wang, G.; Lighter, J.; Elbel, B.; Troxel, A.; Heguy, A.
title: Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City
date: 2021-07-06
journal: nan
DOI: 10.1101/2021.07.05.21259547
sha: 0634b243641db5bf85e1cf04e74b75bd06259591
doc_id: 292882
cord_uid: mjahzh5l

The efficacy of COVID-19 mRNA vaccines is high, but breakthrough infections still occur. We compared the SARS-CoV-2 genomes of 67 breakthrough cases after full vaccination with BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), or JNJ-78436735 (Janssen) to unvaccinated controls (February-April 2021) in metropolitan New York, including their phylogenetic relationship, distribution of variants, and full spike mutation profiles. Their median age was 45 years; seven required hospitalization and one died. Most breakthrough infections (54/67) occurred with B.1.1.7 (Alpha) or B.1.526 (Iota). Among the 7 hospitalized cases, 5 were infected with B.1.1.7, including 1 death. Both unmatched and matched statistical analyses considering age, sex, vaccine type, and study month as covariates supported the null hypothesis of equal variant distributions between vaccinated and unvaccinated in chi-squared and McNemar tests (p>0.1) highlighting a high vaccine efficacy against B.1.1.7 and B.1.526. There was no clear association among breakthroughs between type of vaccine received and variant. In the vaccinated group, spike mutations in the N-terminal domain and receptor-binding domain that have been associated with immune evasion were overrepresented. The evolving dynamic of SARS-Co-V2 variants requires broad genomic analyses of breakthrough infections to provide real-life information on immune escape mediated by circulating variants and their spike mutations.

The novel betacoronavirus SARS-CoV-2 arose as a new human pathogen at the end of 2019, and rapidly spread to every corner of the globe, causing a pandemic of enormous proportions, with 179 million cumulative infections and almost 4 million deaths counted worldwide as of mid-June 2021 1 . As soon as the causative agent was identified and sequenced 2 , massive efforts to develop vaccines were initiated and tested simultaneously in multiple clinical trials. These efforts led to the rapid deployment of several of these vaccines by December 2020, less than a year after the first SARS-CoV-2 viral sequence had been determined. In the United States, vaccination started in December 2020, using two novel mRNA-based vaccines, BNT162b2 (Pfizer/BioNTech), and mRNA-1273 (Moderna), both using the SARS-CoV-2 spike mRNA sequence of the original Wuhan variant. The Janssen COVID-19 vaccine, JNJ-78436735, was also deployed shortly after the mRNA vaccines, and these vaccines were shown to have high efficacy in clinical trials [3] [4] [5] . With millions of people vaccinated in multiple countries, they have proven to be highly effective in the real world [6] [7] [8] [9] [10] [11] [12] , although a very small percentage of breakthrough infections have occurred, as expected [13] [14] [15] [16] [17] [18] [19] [20] [21] . Contemporaneously with the vaccination efforts in several countries, new SARS-CoV-2 variants emerged, four of which were designated by the WHO as variants of concern (VOC), B.1.1.7 or Alpha, B.1.351 or Beta, P.1 or Gamma, and B.1.617.2 or Delta, which arose originally in the UK, South Africa, Brazil, and India, respectively 22, 23 . VOCs are classified as such if they are more transmissible, cause more severe disease or a significant reduction in neutralization by antibodies generated via previous infection or after vaccination. In addition, there are variants of interest (VOI), which carry mutations that have been associated with changes to receptor binding, reduced neutralization by anti-SARS-CoV-2 antibodies, or may increase transmissibility or severity. One of these variants is B.1.526 (Iota), 180901050). Libraries were prepared using Swift Normalase Amplicon SARS-CoV-2 Panel (SNAP) and SARS-CoV-2 additional Genome Coverage Panel (Cat# SN-5X296 core kit, 96rxn), using 10 µl of first strand cDNA, following the manufacturer's instructions 26 . Final libraries were run on Agilent Tapestation 2200 with high sensitivity DNA Screentape to verify the amplicon size of about 450 bp. Normalized pools were run on the Illumina NovaSeq 6000 system with the SP 300 cycle flow cell. Run metrics were paired-end 150 cycles with dual indexing reads. Typically, two pools representing two full 96 well plates (192 samples) were sequenced on each SP300 NovaSeq flow cell.

Sequencing reads were demultiplexed using the Illumina bcl2fastq2 Conversion Software v2.20 and adapters and low-quality bases were trimmed with Trimmomatic v0.36 27 . BWA v0.7.17 28 was utilized for mapping reads to the SARS-CoV-2 reference genome (NC_045512.2, wuhCor1) and mapped reads were soft-clipped to remove SNAP tiled primer sequences using Primerclip v0.3.8 29 . BCFtools v1.9 30 was used to call mutations and assemble consensus sequences, which were then assigned phylogenetic lineage designations according to PANGO nomenclature 31 . Sequences that did not yield a near-complete viral genome (<23,000bp, <4000x coverage) were discarded from further analysis.

Phylogenetic analyses SARS-CoV-2 full genome sequences were aligned using Mafft v.7 32 . The alignment was cropped to base pairs 202-29657 according to the Wuhan-Hu-1 reference to remove N-and C-terminal regions with unassigned base pairs. Maximum likelihood IQ trees were performed using the IQ-TREE XSEDE tool, multicore version 2.1.2, on the Cipres Science gateway v.3.3 33 . GTR+I+G was chosen as the best-fit substitution model. Support values were generated with 1,000 bootstrap replicates and the ultrafast bootstrapping method. Phylogenetic trees were visualized in Interactive Tree Of Life (iTOL) v.6 34 . The tree was constructed using 67 vaccine breakthrough and 1,187 unvaccinated control SARS-CoV-2 sequences from our NYU cohort (greater NYC area) together with 3,802 global reference sequences for a total of 5,056 SARS-CoV-2 genomic sequences. The reference sequences were retrieved from a Nextstrain build with North America-focused global subsampling [4] and included 1,361 other US sequences.

Spike amino acid counts and calculations of site-specific mutation frequencies compared to Wuhan-Hu-1 as reference were done on MAFFT-aligned SARS-CoV-2 sequences using R 35 and R Studio 36 using scripts based on the seqinr and tidyverse (dplyr, lubridate, magrittr) packages. The calculations exclusively considered residues that were accurately covered by sequencing, i.e., non-ambiguous characters and gaps. Fisher exact tests and multiplicity corrections (Benjamini-Hochberg) were done in Program R/RStudio. Multiplicity corrected P values (q) <0.05 were considered significant. Highlighter analyses were performed on MAFFT-aligned SARS-CoV-2 amino acid sequences of the spike genomic region. SARS-CoV-2 vaccine breakthrough sequences were compared to Wuhan-Hu-1 as master using the Highlighter tool provided by the Los Alamos HIV sequence database 37 . To address confounding and other sources of bias arising from the use of observational data, we estimated a propensity score for the likelihood of full vaccination 38 , and successfully matched all 67 vaccinated to unvaccinated patients, including age, sex, county of residence, and study month (February, March, and April 2021) as covariates. The standardized mean difference between the matched pairs was 0.0125, reduced by 99.7 percent from 0.590 prior to matching. Table 2 ). Thus, vaccinated and unvaccinated individuals in the metropolitan New York area are similarly affected by the regionally circulating VOCs and VOIs. In addition, there is no clear association among vaccinated patients between type of vaccine received and Pango lineage (chi-squared test, p=0.36).

As a way to ascertain potential bias in our sampling, we carried out a phylogenetic analysis of our 67 breakthrough sequences in the context of 1,187 unvaccinated SARS-CoV-2-positive controls (selected randomly as part of our greater New York catchment area genomic surveillance) together with sub-sampled sequences from the United States as well as globally, the latter two groups based on Nextstrain builds of GISAID sequences (Figure 2) . The main variants circulating in the New York area between the months of February and April 2021 were B.1.1.7 and B.1.526 (purple). Accordingly, our vaccine breakthrough samples (orange branch symbols and gray rays) mostly engaged B.1.1.7 and B.1.526 clades and were interspersed among the unvaccinated controls as well as other United States sequences. There was no evidence of extensive clustering that might indicate onward transmissions or transmission chains of vaccine breakthrough infections. Instead, they were widely distributed and appeared to mostly involve independent clusters of infections.

To screen whether vaccine breakthrough preferentially occurred with distinct vaccine escape mutations, we performed a comparative analysis of spike mutations between case and control groups. In our aligned data set of 67 vaccine breakthrough and 1,187 unvaccinated control sequences, spike mutations (compared to Wuhan-Hu-1) occurred at 233 amino acid residues. While most of these sites were more frequently mutated in control cases (191 sites), and one site (D614) being equally mutated in both groups (100% D614G), 41 sites exhibited increased mutation rates in the vaccine breakthrough group ( Figure 3A) . Interestingly, the degree of enrichment (Δ mut) was higher at the 41 breakthrough-enriched sites compared to the 191 sites enriched in controls. Contributing factors presumably included random mutations in the absence of immune pressure in controls, adaptive selection of immune escape mutations in vaccine breakthroughs, but also uneven case numbers in both groups. When we disregarded unique mutations per data set in our calculations, the mutation analysis yielded 21 distinct spike sites with enriched mutations in breakthrough infections ( Figure 3A , Supplementary Table 4 ). Although individual sites did not achieve significance in Fisher's exact tests, the array of sieved mutation sites drew a striking pattern of N-terminal domain (NTD) deletions (ΔV69-H70 and ΔY144), receptor-binding domain (RBD) mutations (K417, S477, E484, and N501), a mutation near the furin binding site (P681X), and also C-terminal mutations (T1027X and D1118X), all of which have been associated with enhanced immune evasion or ACE2 receptor binding, and/or recurring mutations in emerging VOCs/VOIs 22, 42 .

Our data from a large metropolitan healthcare system in the greater New York City area underline a high vaccine efficacy in fully vaccinated individuals, 14 days or longer post-last dose of vaccination. Efficacy is maintained against several circulating variants including VOCs and VOIs. Compared to the large number of SARS-CoV-2 infections among unvaccinated individuals, the recorded breakthrough cases between February and April 2021 (n=67) remained at~1% of total infections, with the caveat that both breakthrough cases as well as unvaccinated controls were not exhaustively screened and covered.

Despite the overall effectiveness of vaccination, our full spike mutation analysis revealed a broad set of spike mutations (n=21) to be elevated in the vaccine breakthrough group. It indicates that adaptive selection is in progress that may subsequently come into full effect. At this point, the breakthrough cases and differences in mutation rates between case and control groups are still too low to draw meaningful conclusions. However, the overrepresentation of functionally important spike mutations including NTD deletions ΔH69-V70 and ΔY144 together with RBD mutations K417X, S477X, E484X, and N501X as well as P681X (near the S1/S2 interface) in the absence of a clear elevation of VOCs or VOIs may indicate a starting sieve effect at individual or combinations of functional mutations. Spike mutations and deletions reported to confer neutralization escape in vitro 23, 43, 44 might thus be responsible for a sieve effect in a real-life situation, i.e., among vaccinated individuals.

During the time of our sample and data collection, there were two major variants arising in the New York City metro area constituting about two thirds of all cases, B.1.1.7, which was first reported in the UK 45 , and B.1.526, which arose in New York City around December of 2020 24, 25 . B.1.1.7 was deemed a variant of concern by the WHO and CDC and was associated with higher viral loads in infected individuals 40, 41 , enhanced epidemiological spread [45] [46] [47] , an extended window of acute infection 48 , less effective innate and adaptive immune clearance 49 , and increased death rates in elderly patients and/or individuals with comorbidities 50-53 . The B.1.1.7 variant, e.g., through the RBD N501Y mutation but also through NTD deletions, acquired an enhanced affinity to ACE2, higher infectivity and virulence [54] [55] [56] [57] , while maintaining sensitivity to neutralization though with slightly impaired nAb titers 54, 58-60 . The B.1.526 variant and its derivatives were designated VOI because of the presence of RBD mutations such as E484K or S477N that favor immune evasion 23, 25 .

To study whether the more transmissible B.1.1.7 or B.1.526 because of its critical RBD mutations and prevalence/place of origin in our city were overrepresented in the breakthrough cases, we performed a comparative statistical analysis. Extending a few other studies reported so far 13-21 , we focused on a strict threshold of 14 days post last dose of vaccination, and we performed both unmatched and matched analyses side-by-side. We adjusted the confounding factors sex, age, study month, and residence area, though we are aware that other confounding factors such as biased sampling or behavioral differences between groups might also play a role. Our finding that B.1.1.7 and B.1.526 are not preferentially represented in the vaccine breakthrough group but distributed at similar proportions as other variants in case and control groups suggests that the studied mRNA vaccines are comparably effective against these predominant variants in the NYC area. This is in agreement with recent data from Israel evaluating B.1.1.7 in this context 17 . A sieve effect of the B.1.526 variant has not been studied in this detail, except for two studies with small sample sizes of n=2 and n=11 that did not allow strong conclusions 14, 19 . A recent CDC study reported a total number of 10,262 SARS-CoV-2 vaccine breakthrough infections across the USA as of end-April 2021 causing hospitalization in 10% of cases (n=995) 20 , a rate identical to our study.

Interestingly, the majority of our breakthrough infections had low Ct values (Ct <35), implying a moderate to high viral load in these cases, at least in the nasopharynx from where our samples were collected. These high viral loads suggest the possibility of transmission to others 61 . Although our phylogenetic analysis does not provide evidence of transmission to others from our breakthrough cases at this time, this should be expected with the growing number of breakthrough cases in the next months. This may have significant epidemiologic and clinical significance if transmissible breakthrough infections carry specific spike mutations associated with immune evasion.

In conclusion, our data indicate that vaccine breakthrough in fully mRNA-vaccinated individuals is not more frequent with the VOC Alpha or the NY local VOI Iota, which underlines the high efficacy of mRNA COVID-19 vaccines against different variants. The Alpha variant appears overrepresented in the hospitalized group, though the low case numbers of hospitalizations do not allow firm conclusions. The increased presence of mutations in key regions of the spike protein in the vaccine breakthrough group is of potential concern and requires continued monitoring. Genomic surveillance of vaccine breakthrough cases should be carried out on a broader scale throughout the United States and the entire word to achieve higher case numbers and the inclusion of different VOCs and VOIs.

Ralf Duerr, MD, PhD designed the study, analyzed data and wrote the manuscript; Dacia Dimartino, PhD generated sequencing data; Christian Marier analyzed genomic data; Paul Zappile generated sequencing data; Guiqing Wang, MD, PhD collected samples and performed clinical SARS-CoV-2 detection; Jennifer Lighter, MD reviewed clinical information; Brian Elbel, PhD monitored epidemiological data and generated lists of breakthrough infections; Andrea Troxel, PhD performed statistical analyses; Adriana Heguy, PhD designed the study, generated genomic data and wrote the manuscript. All authors reviewed and edited the manuscript.

Tables. Table 1 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 6, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 6, 2021. ; All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.05.21259547 doi: medRxiv preprint Figure 2 . Maximum likelihood tree of SARS-CoV-2 vaccine breakthrough, unvaccinated matched control, and global reference sequences. IQ tree of 5,056 SARS-CoV-2 full genome sequences (base pairs 202-29,657 according to Wuhan-Hu-1 as reference), including 67 vaccine breakthrough (orange) and 1,187 unvaccinated control SARS-CoV-2 sequences from our NYU cohort (greater NYC area) (purple) together with 1,361 other US (cyan) and 2,441 non-US global reference sequences (black). The tree was generated with a GTR+I+G substitution model and 1,000 bootstrap replicates, and the substitution scale of the tree is indicated at the bottom right. The branches of the tree are colored as indicated. Vaccine breakthrough sequences are additionally highlighted by orange triangles as branch symbols and gray rays radiating from the root to the outer rim of the tree. Hospitalizations due to COVID-19 among the vaccine breakthrough infections are indicated by black triangles (h). The variants responsible for most vaccine breakthrough infections in our study cohort are labeled with respective Pango lineages (WHO classification in parenthesis).

Site-specific spike mutation analysis in SARS-CoV-2 vaccine breakthrough sequences compared to unvaccinated matched controls. A) Comparison of site-specific amino acid mutation (mut) frequencies in spike in 67 vaccine breakthrough sequences (Vacc) compared to 1,187 unvaccinated matched controls (Unvacc) from the same cohort. The Wuhan-Hu-1 sequence served as reference to call mutations per site, and all spike mutation sites of the study sequences are shown along the x-axis according to their spike position (n=233). The mirror plot displays differences of mutation frequencies between Vacc and Unvacc groups; orange bars (top) refer to higher mutation rates in Vacc sequences, whereas black bars (bottom) refer to higher mutation rates in Unvacc matched controls. B) Enrichment of spike mutations in SARS-CoV-2 vaccine breakthrough sequences. All sites with greater spike mutation rates in Vacc compared to Unvacc controls are shown; unique occurrences of mutations were disregarded. Mutation sites in the spike N-terminal domain (NTD), receptor binding domain (RBD), and S1/S2 interface region that have been associated with variants of concern and/or neutralization immune escape are highlighted. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 6, 2021. , M G89S, N A398V, N D3L, N G204R, N R203K, N S235F,  NS3 L15F, NS8 Q27stop, NS8 R52I, NS8 Y73C, NSP3 A890D, NSP3 I1412T, NSP3 T183I, NSP4 F17L, Spike T716I, M I82T, N G96C, N K127R, N L224F, N T205I,  NS3 Q57H, NSP2 S122F, NSP2 T85I, NSP3 A333S, NSP4 T492I, NSP6 T181I, NSP12 A97V, All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 6, 2021. ; https://doi.org/10.1101/2021.07.05.21259547 doi: medRxiv preprint

Total RNA (11 µl) was converted to first strand cDNA by random priming using the Superscript IV first-strand synthesis system (Invitrogen, ref# 180901050). Random priming was performed as follows: 65˚C for 5 mins, cooled on ice followed by addition of mix to run cDNA first strand synthesis 23˚C 10mins, 50˚C for 1 hour, 80˚C for 10 mins, and 4˚C hold. Libraries were prepared using Swift Normalase Amplicon Panel (SNAP) SARS-CoV-2 and Sar-Cov-2 additional Genome Coverage (Cat# SN-5X296 core kit, 96rxn), using 10 µl of first strand cDNA, following the manufacturer's instruction: https://swiftbiosci.com/wp-content/uploads/2021/06/PRT-028-Swift-Normalase-Amplicon-Panels-SNAP-SARS-CoV-2-Panels-Rev-9.pdf). First step incorporated tiled primer pairs which target and enrich for the entire 29.9kb covid-19 viral genome (NCBI Reference Sequence NC_045512.2) during multiplex PCR. Multiplex PCR was run as follows: 98˚C 30 secs, 4 repeating cycles of 98˚C/ 10secs, 61˚C/5mins, 65˚C/1min. 24 repeating cycles of 98˚C/10secs, 64˚C/1min followed by 1 cycle of 65˚C for 1 min and held at 4 ˚C. The multiplexed samples were cleaned with 1x volume room temperature Ampure XP beads (Beckman Coulter, #A63882) for 5 mins, washed with 80% ethanol twice, and beads were resuspended in 17.4ul of TE buffer (part of swift kit). Indexing reagent mix was added to the resuspended beads. One unique SNAP UD dual indexing primer pair was added to each sample. Indexing PCR was run at 37˚C/20mins, 98˚C/30secs, 9 repeating cycles of 98˚C/10secs, 60˚C/30secs, 66˚C/1min. After indexing PCR was completed, samples were cleaned with 32.5ul of PEG NaCl solution (provided in swift kit, 5min bind time, 80% ethanol wash x2) and eluted in 20ul of post PCR TE buffer. Final libraries were run on Agilent Tapestation 2200 with high sensitivity DNA Screentape to verify amplicon size of about 450 bp. Samples were pooled according to the enzymatic normalase step. The loading concentration for the normalized pool was verified on QPCRusing the Kapa library quantification complete kit (Kapa-Roche, #KK4824) run on the Bio-Rad CFX384 Real-time system. Normalized pools were run on the Illumina NovaSeq 6000 system with the SP 300 cycle flow cell. Run metrics were paired end 150 cycles with dual indexing reads. Typically, 2 pools representing 2 full 96 well plates (192 samples) were sequenced on each SP300 NovaSeq flow cell. 1]>20" --output-type v | bcftools filter -e "IMF<0.5" --output-type v To generate viral sequences, the output in VCF format was applied to the reference sequence using `bcftools consensus` while the BEDTools v2.30.0 utilities (Quinlan and Hall 2010), "genomecov" (with the '-bga' option to report depth at each base including zero coverage sites), "merge" (for creating a BED file of low depth sites with <1000x coverage to be masked), and "maskfasta" in conjunction with the multiple sequence alignment program, MAFFT v4.471 (Katoh et al. 2002) in '--auto' mode, were used in the production of final consensus sequences with all bases below 1000x coverage masked and both non-targeted ends of the sequences trimmed. Sequences with fewer than 23,000 bp with at least 4000x coverage were discarded from further analysis for having not yielded a near-complete SARS-CoV-2 genome, resulting in 1,254 final sequences suitable for downstream analysis (Supplemental Table) . Each assembled SARS-CoV-2 genome sequence was assigned the most likely phylogenetic lineage according to Phylogenetic Assignment of Named Global Outbreak Lineages (PANGO) nomenclature (Rambaut et al. 2020 ) using the PANGO lineage tool (version: 2021-06-05).

COVID-19 Coronavirus Pandemic

A new coronavirus associated with human respiratory disease in China

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers -Eight U.S. Locations

COVID-19 dynamics after a national immunization program in Israel

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of realworld data

Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel -33

Adverse Outcomes Associated with SARS-CoV-2 variant B.1.351 Infection in Vaccinated Residents of a Long Term Care Home

Rapid Emergence and Epidemiologic Characteristics of the SARS-CoV-2 B.1.526 Variant

Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members

The SARS-CoV-2 mRNA vaccine breakthrough infection phenotype includes significant symptoms, live virus shedding, and viral genetic diversity

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Post-vaccination SARS-CoV-2 infections and incidence of the B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center. medRxiv

Cavanaugh AM, et al. COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program -Kentucky

SARS-CoV-2 Portrayed Against HIV: Contrary Viral Strategies in Similar Disguise

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species

SARS-CoV-2 lineage B.1.526 emerging in the New York region detected by software utility created to query the spike mutational landscape

A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York

Fast and accurate short read alignment with Burrows-Wheeler transform

The Sequence Alignment/Map format and SAMtools

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Creating the CIPRES Science Gateway for Inference of Large Phylogenetic Trees

Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group

Nonparametric Preprocessing for Parametric Causal Inference

S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR

Genomic characteristics and clinical effect of the emergent SARS-CoV

UK: a whole-genome sequencing and hospital-based cohort study

The emerging plasticity of SARS-CoV-2. Science

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2

Virological and serological characterization of critically ill patients with COVID-19 in the UK: Interactions of viral load, antibody status and B.1.1.7 variant infection

Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern

Covid-19: New UK variant may be linked to increased death rate, early data indicate

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the variant of concern lineage B.1.1.7. Cell reports

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. The Lancet

BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations in Israel

Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study

Acknowledgements. The authors wish to thank Vincent Setang and NYU Langone Health DataCore for support extracting the data for this study from clinical databases, Dr. Maria Agüero-Rosenfeld and the clinical laboratory technicians for assistance in testing, saving and retrieving specimens, especially Joanna Fung for her assistance with RNA extraction project. We also thank Dr. Joan Cangiarella for her continuous support of genomic surveillance for SARS-CoV-2 at NYULH, including providing institutional funding for this study. We are grateful to the authors and submitting laboratories who deposited data in GISAID, in particular to those whose sequences we used to create the phylogenetic tree. These are all named in Supplemental Table  5 . The NYULH Genome Technology Center is partially supported by the Cancer Center Support Grant P30CA016087 at the Laura and Isaac Perlmutter Cancer Center.